ADC Therapeutics (NYSE:ADCT) reported first-quarter 2026 net product revenue growth for its lymphoma therapy ZYNLONTA and reiterated expectations for multiple upcoming clinical milestones, led by a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

ADC Therapeutics Ltd ((ADCT)) has held its Q3 earnings call. Read on for the main highlights of the call. ADC Therapeutics Ltd’s recent earnings call painted a picture of both stability and challenges ...

JS212 combines dual-targeting antibody technology with a cytotoxic payload, representing a next-generation therapeutic. BioDlink provided end-to-end development and manufacturing support, showcasing ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted ...

(RTTNews) - Next Cure Inc. (NXTC) outlined steady clinical and operational momentum across its two antibody-drug conjugate programs while reporting a preliminary year-end cash position that supports ...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format ...

ADC Therapeutics Ltd’s recent earnings call painted a picture of both stability and challenges. The company reported stable revenues and promising clinical trial outcomes, underscored by a robust ...